Analyst Reco. Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 11/07/2025 BST			5-day change	1st Jan Change
18.31 ^USD	-2.92%		+9.05%	-2.61%

07-08	Arrowhead Pharmaceuticals, Inc., Q2 2025 Earnings Call, May 12, 2025
07-08	Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia	CI

Analyst Reco.

UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $63 From $71, Maintains Buy Rating	05-14	MT
RBC Adjusts Price Target on Arrowhead Pharmaceuticals to $40 From $42, Maintains Outperform Speculative Risk Rating	05-13	MT
B. Riley Adjusts Price Target on Arrowhead Pharmaceuticals to $38 From $51, Keeps Buy Rating	02-14	MT
B. Riley Lowers Price Target on Arrowhead Pharmaceuticals to $51 From $55, Keeps Buy Rating	12-12	MT
HC Wainwright Raises Price Target on Arrowhead Pharmaceuticals to $80 From $60, Keeps Buy Rating	12-03	MT
Analyst recommendations: Nvidia, Workday, Doordash, Nutanix, T-Mobile...	11-27
Analyst recommendations: Estee Lauder, Sentinelone, Snowflake, Wolfspeed, Admiral...	22/08/24
Analyst recommendations: Epam Systems, Five9, T-Mobile, Lyft, Under Armour...	09/08/24
Analyst recommendations: CrowdStrike, Johnson & Johnson, Netflix, Nvidia, Snap...	23/07/24
HC Wainwright Cuts Price Target on Arrowhead Pharmaceuticals to $60 From $90, Keeps Buy Rating	05/07/24	MT
UBS Cuts Price Target on Arrowhead Pharmaceuticals to $71 From $75, Keeps Buy Rating	10/05/24	MT
B. Riley Adjusts Arrowhead Pharmaceuticals' PT to $55 From $50, Keeps Buy Rating	08/02/24	MT
UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $75 From $78, Maintains Buy Rating	07/02/24	MT
BofA Securities Initiates Arrowhead Pharmaceuticals at Buy Rating With $29 Price Target	04/12/23	MT
B. Riley Lowers Arrowhead Pharmaceuticals' Price Target to $50 From $60, Notes Higher Cash Burn; Keeps Buy Rating	04/12/23	MT
Morgan Stanley Cuts Price Target on Arrowhead Pharmaceuticals to $37 From $40, Maintains Equal-Weight Rating	30/11/23	MT
TD Cowen Starts Arrowhead Pharmaceuticals at Outperform	21/07/23	MT
Piper Sandler Adjusts Price Target on Arrowhead Pharmaceuticals to $59 From $52, Maintains Overweight Rating	02/06/23	MT
SVB Leerink Downgrades Arrowhead Pharmaceuticals to Market Perform From Outperform, Price Target is $40	12/05/23	MT
Goldman Sachs Adjusts Arrowhead Pharmaceuticals' Price Target to $73 From $65, Keeps Buy Rating	03/05/23	MT
Morgan Stanley Raises Price Target on Arrowhead Pharmaceuticals to $40 From $37, Maintains Equalweight Rating	03/05/23	MT
SVB Securities Upgrades Arrowhead Pharmaceuticals to Outperform From Market Perform, Raises PT to $35 From $21	12/04/23	MT
RBC Capital Adjusts Arrowhead Pharmaceuticals Price Target to $60 From $77, Maintains Outperform - Speculative Risk Rating	06/04/23	MT
Bernstein Initiates Arrowhead Pharmaceuticals at Market Perform With $27 Price Target	21/03/23	MT
B. Riley Lowers Arrowhead Pharmaceuticals' Price Target to $55 From $59, Keeps Buy Rating	08/02/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Analyst Reco.

Filters